Business
APOTEA: Strong RX-driven growth and profitability, with Varberg ramp-up and robust cash flow
APOTEA: Strong RX-driven growth and profitability, with Varberg ramp-up and robust cash flow
About this update from Apotea Ab
Revenue grew 9.9% to SEK 1.826 billion, driven by strong RX demand and stable gross margins. Profitability improved, with an adjusted EBIT margin of 5.4%, and the Varberg facility is set to boost future efficiency. Net cash position remains strong.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.